

Jan. 2026 updates to prior authorizations and post-service claim edits

Security Health Plan requires prior authorization (PA) and post-service claim edits (PSCE) on office-administered, medically billed medications to ensure coverage and appropriate payment for those services. The following medications will be reviewed for medical necessity by Prime Therapeutics for PA and PSCE starting Jan. 1, 2026:

- Papzimeos[®] (zopapogene imadenovec-drba)
- Gammagard liquid erc[®] (immune globulin infusion (human))
- Avgemsi[®] (gemcitabine)
- Lynozyfic[®] (linvoseltamab-gcpt)
- Zusduri[®] (mitomycin)
- Andembry[®] (garadacimab-gxii)
- Starjemza[®] (ustekinumab-hmny)
- Camcevi Etm (leuprolide) - **PSCE only**
- Kyxata (carboplatin)
- BILDYOS (denosumab-nxxp)
- Bilprevda (denosumab-nxxp)

This list includes new additions and represents a partial list of the prior authorizations and post-service claim edits required of members and providers to ensure payment for services. Prior authorizations will be managed through Security Health Plan's specialty pharmacy medication partner, Prime Therapeutics. Please call 1-800-424-8243 or visit their website for details: <https://gatewaypa.com/>.

You can review the complete list of medications that require prior authorizations or post-service claim edits on our website at www.securityhealth.org/providers/medical-pharmacy. If you have any questions, please contact Security Health Plan Provider Relations at **1-800-548-1224**.